Connect Biopharma Holdings Limited (CNTB)
| Previous Close | 1.5100 |
| Open | 1.5000 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 1.4301 - 1.5000 |
| 52 Week Range | 0.5350 - 2.8400 |
| Volume | |
| Avg. Volume | 161,796 |
| Market Cap | 78.803M |
| Beta (5Y Monthly) | -0.49 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.0800 |
| Earnings Date | Apr 16, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.00 |
GlobeNewswireConnect Biopharma to Present a Late-Breaking Abstract at the American Thoracic Society (ATS) 2024 International Conference on the Positive Results from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma
SAN DIEGO, CA and TAICANG, China, May 07, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today announced data from its global Phase 2b trial of rademikibart in patients with moderate-to-severe asthma was accepted as a late-break
NewsfileStonegate Healthcare Partners Updates Report on Transformative Therapies for Pruritus Management
Dallas, Texas--(Newsfile Corp. - May 2, 2024) - Stonegate Healthcare Partners is providing an update on the publication of its report, titled "Transformative Therapies for Pruritus Management." This comprehensive report delves into the critical issue of pruritus, or chronic itch, and its impact on patients, particularly those suffering from Primary Biliary Cholangitis (PBC), an autoimmune liver disease. To view the ...
- GlobeNewswire
Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update
Reported two positive readouts for rademikibart, the Company’s lead asset, from the Global Phase 2b trial in moderate-to-severe persistent asthma and from the China pivotal trial in moderate-to-severe atopic dermatitis (AD)Type C meeting in AD and End-of-Phase 2 (EoP2) meeting in asthma have been scheduled with the U.S. Food and Drug Administration (FDA) in Q2 2024 to discuss trial results and proposed registrational programsGranted Simcere the exclusive rights to develop, manufacture, and comme
